EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery and preclinical evaluation of ZLC853 as a potential clinical candidate covalently targeting CDK12/13 kinases

Kaijie Zhou, Licheng Zhou, Jean C Tien, Weixue Huang, Wenyan Liu, Xinyu Sun, Bohai Fan, Xin Huang, Jun Wang, Yu Chang, Jianzhang Yang, Yue Yin und 14 weitere

Acta Pharmaceutica Sinica B · 2026-11 · 16 (11) · 7554-7572

DOI: 10.1016/j.apsb.2026.07.041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Kaijie Zhou und 25 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Howard Hughes Medical Institute, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Previous studies highlight the therapeutic promise of inhibiting cyclin-dependent kinases 12 and 13 (CDK12/13) for castration-resistant prostate cancer (CRPC) and other malignancies. However, developing small molecule modulators of CDK12/13 that exhibit an optimal combination of potency, selectivity and favorable pharmacokinetics (PK) remains challenging. In this study, we present ZLC853, a potent, selective, and orally bioavailable covalent inhibitor of CDK12/13 developed through PK-oriented optimization of our previously reported inhibitor YJZ5118. ZLC853 potently inhibited CDK12 and CDK13 with IC50 values of 40.0 and 18.2 nmol/L, respectively, and displayed exceptional kinase selectivity in a comprehensive KinomeScan assay. Its covalent binding mechanism was unequivocally validated through mass spectrometry, co-crystal structure analysis, cellular pull-down assays, and washout experiments. Functionally, ZLC853 suppressed the transcription of DNA damage response genes, induced DNA damage, and promoted apoptosis. Additionally, ZLC853 exhibited good oral bioavailability and robust antitumor activity across multiple prostate cancer models, both in vitro and in vivo, supporting it as a promising candidate for clinical investigation.

Schlagwörter

Stichwörter der Autor:innen

CDK12CDK13Covalent inhibitorCrystal structureOral bioavailabilityPotential clinical candidateProstate cancerRational design

Autor:innen und Institutionen

  • State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.
  • University of Chinese Academy of Sciences, Beijing 101408, China.
  • International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), Guangzhou City Key Laboratory of Precision Chemical Drug Developme…
  • Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
  • Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA.
  • National Facility for Protein Science in Shanghai, Shanghai Advanced Research Institute, Chinese Academy of Science, Shanghai 201210, China.

Förderung

  • NCI NIH HHS
  • Howard Hughes Medical Institute
  • National Natural Science Foundation of China
  • National Institutes of Health National Cancer Institute

Zitieren

APA

Zhou, K., Zhou, L., Tien, J. C., Huang, W., Liu, W., Sun, X., Fan, B., Huang, X., Wang, J., Chang, Y., Yang, J., Yin, Y., Su, C., Li, Q., Mannan, R., Mahapatra, S., Cheng, Y., Todd, A. J., Wheeler, C. E., …, & Ding, K. (2026). Discovery and preclinical evaluation of ZLC853 as a potential clinical candidate covalently targeting CDK12/13 kinases. Acta Pharmaceutica Sinica B, 16(11), 7554-7572. https://doi.org/10.1016/j.apsb.2026.07.041

Vancouver

Zhou K, Zhou L, Tien JC, Huang W, Liu W, Sun X, et al. Discovery and preclinical evaluation of ZLC853 as a potential clinical candidate covalently targeting CDK12/13 kinases. Acta Pharmaceutica Sinica B. 2026;16(11):7554-7572. doi:10.1016/j.apsb.2026.07.041

BibTeX
@article{Zhou2026,
  author = {Zhou, Kaijie and Zhou, Licheng and Tien, Jean C and Huang, Weixue and Liu, Wenyan and Sun, Xinyu and Fan, Bohai and Huang, Xin and Wang, Jun and Chang, Yu and Yang, Jianzhang and Yin, Yue and Su, Chen and Li, Qingrun and Mannan, Rahul and Mahapatra, Somnath and Cheng, Yunhui and Todd, Abigail J and Wheeler, Christina E and Li, Shuqin and Zhou, Yang and Ren, Xiaomei and Wang, George Xiaoju and Wang, Zhen and Chinnaiyan, Arul M and Ding, Ke},
  title = {Discovery and preclinical evaluation of ZLC853 as a potential clinical candidate covalently targeting CDK12/13 kinases},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  volume = {16},
  number = {11},
  pages = {7554--7572},
  doi = {10.1016/j.apsb.2026.07.041}
}
Kostenlos starten →